Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Autolus Therapeutics (AUTL) Revenue (2017 - 2025)

Historic Revenue for Autolus Therapeutics (AUTL) over the last 9 years, with Q3 2025 value amounting to $21.2 million.

  • Autolus Therapeutics' Revenue changed N/A to $21.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $51.1 million, marking a year-over-year increase of 40621.78%. This contributed to the annual value of $10.1 million for FY2024, which is 49599.53% up from last year.
  • According to the latest figures from Q3 2025, Autolus Therapeutics' Revenue is $21.2 million.
  • In the past 5 years, Autolus Therapeutics' Revenue ranged from a high of $236.0 million in Q3 2021 and a low of $29000.0 during Q4 2024
  • Moreover, its 5-year median value for Revenue was $3.0 million (2022), whereas its average is $25.4 million.
  • Its Revenue has fluctuated over the past 5 years, first skyrocketed by 5378127.85% in 2021, then crashed by 9899.62% in 2022.
  • Over the past 5 years, Autolus Therapeutics' Revenue (Quarter) stood at $236.0 million in 2021, then plummeted by 98.45% to $3.7 million in 2022, then tumbled by 88.9% to $406000.0 in 2023, then plummeted by 92.86% to $29000.0 in 2024, then surged by 72982.76% to $21.2 million in 2025.
  • Its Revenue was $21.2 million in Q3 2025, compared to $20.9 million in Q2 2025 and $9.0 million in Q1 2025.